TARBOD
LIVE

Serial Number

97312018

Owner

Booster Therapeutics GmbH

Attorney

Nicholas D. Wells

Filing Date

Mar 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

TARBOD Trademark

Serial Number: 97312018 • Registration: 7656979

TARBOD is a trademark filed by Booster Therapeutics GmbH on March 14, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Booster Therapeutics GmbH (3 trademarks)

Schluterstr 36
Berlin D-10629 , DE

Entity Type: 16

Trademark Details

Filing Date

March 14, 2022

Registration Date

January 21, 2025

Published for Opposition

December 3, 2024

Goods & Services

Pharmaceutical preparations for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases, heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases; Compound drugs and pharmaceuticals for the use in the field of oncology, immunology, inflammatory diseases, and central nervous system disorders to treat the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins; Compound drugs and pharmaceuticals for the treatment of the pathologies of aging, neurodegenerative diseases, brain diseases, ocular diseases, skin disorders and skin conditions, kidney diseases, liver diseases , heart diseases, urology disorders, circulatory disorders, muscle diseases, pancreas diseases, digestive system diseases, lung diseases, memory loss, fatigue, eye strain, eye disease, hearing loss, hair loss, sexual disfunction and reproductive system diseases, by degrading disease-causing cellular proteins

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 21, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 21, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 3, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 3, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 5, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 24, 2024 CRFA
ASSIGNED TO LIE
Oct 24, 2024 ALIE
ASSIGNED TO LIE
Oct 24, 2024 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 19, 2024 ERSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 22, 2023 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 14, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 14, 2023 GNSL
SUSPENSION LETTER WRITTEN
Apr 14, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 25, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 24, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 24, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 28, 2022 GNRN
NON-FINAL ACTION E-MAILED
Dec 28, 2022 GNRT
NON-FINAL ACTION WRITTEN
Dec 28, 2022 CNRT
ASSIGNED TO EXAMINER
Dec 23, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 18, 2022 NWOS
NEW APPLICATION ENTERED
Mar 17, 2022 NWAP